In patients with hematologic malignancies, what were the most frequently reported adverse events attributed to Kepivance® in the registrational clinical trials?
The most frequently reported adverse reactions attributed to Kepivance® in registrational trials were rash, erythema, edema, pruritus, dysesthesia, mouth/tongue thickness or discoloration, and taste alteration.1,2 Most of the side effects were consistent with the pharmacologic action of Kepivance® on skin and oral epithelium, generally mild to moderate in severity, and reversible.2
Related Questions
- In patients with hematologic malignancies, what were the most frequently reported adverse events attributed to Kepivance® in the registrational clinical trials?
- What were the most serious adverse events reported in the registrational clinical trials of Kepivance®?
- Do the expected complications of postpartum bleeding need to be reported as adverse events?
